Articles by Ray Dogum

1. GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers 11/24/2025

   General Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.

2. From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025 11/20/2025

   Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.

3. Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs 11/13/2025

   According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.

4. OpenFold3 Released: Redefining The Limits Of Protein Prediction Models 11/4/2025

   OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.

5. Video Spotlight: Where Science Meets Magic with MIT Institute Professor Robert S. Langer 10/29/2025

   Drug Discovery Online interviews MIT’s Bob Langer on biomedical innovation, personalized medicine, longevity, and entrepreneurship—highlighting his journey, lab impact, and personal discipline.

6. Discovery On Hold: How Shutdowns Stall Science And Shake Trust 10/10/2025

   When the federal government shuts down and appropriations lapse, the ripple effects reach deep into early drug development efforts. FDA slows regulatory intake, NIH freezes grant reviews and awards, clinical trials are disrupted, and talent pipelines tighten as student and work visas remain in limbo.

7. Tyra Crystallizing The First Oral FGFR3 Therapy For Achondroplasia 9/30/2025

   Tyra Biosciences is using its SNÅP drug discovery platform to develop dabogratinib, the first oral FGFR3-selective therapy for achondroplasia, currently recruiting patients in Phase 2 trials.

8. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 2) 9/19/2025

   Part 2 of 2 - An Interview with Alex (Aleksandrs Zavoronkovs) Zhavoronkov, Ph.D. , Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine.

9. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 1) 9/18/2025

   An Interview with Alex Zhavoronkov, Ph.D. Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine. Founded in 2014, Insilico Medicine, is one of the earliest AI-driven biotech companies and one of the few who have pipeline drugs in Phase II trials.

10. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around.